A randomised controlled comparison of Campath-Tacrolimus vs IL2R MoAb-tacrolimus/mycophenolate mofetil as induction-maintenance immunosuppression in kidney transplantation.

Trial Profile

A randomised controlled comparison of Campath-Tacrolimus vs IL2R MoAb-tacrolimus/mycophenolate mofetil as induction-maintenance immunosuppression in kidney transplantation.

Completed
Phase of Trial: Phase IV

Latest Information Update: 31 Jul 2014

At a glance

  • Drugs Alemtuzumab; Daclizumab; Mycophenolate mofetil; Tacrolimus
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Acronyms CamTac
  • Most Recent Events

    • 09 Feb 2012 Actual end date (Dec 2008) added as reported by ISRCTN: Current Controlled Trials.
    • 09 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ISRCTN: Current Controlled Trials.
    • 02 Sep 2009 Results reported at ESOT 2009.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top